Search research articles
Contact Us
Filters
Showing results (11-20 of 33) with videos related to
Page
of 4
Sort By:
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
October 20, 2021
Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling
Felicitas Kuehne, Ursula Rochau, Noman Paracha, et al.
Advances in Therapy
|
February 17, 2017
Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial
Alison Griffiths, Noman Paracha, Andrew Davies, et al.
Journal of Medical Economics
|
January 18, 2020
Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France
Sivignon Marine, Roze Stéphane, Plommet Nicolas, et al.
European Urology Focus
|
April 18, 2026
Health-related Quality of Life With ARPIs in mHSPC: Insights From a Network Meta-analysis
Neal D Shore, Noman Paracha, Howard Thom, et al.
Pharmacoeconomics
|
October 18, 2021
Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom
Siu Hing Lo, Ksenija Gorni, C Simone Sutherland, et al.
Pharmacoeconomics
|
August 18, 2025
Developing a Comprehensive Framework for Cost-Effectiveness Evaluation in Metastatic Castration-Sensitive Prostate Cancer: Insights from a Systematic Review
Christopher G Fawsitt, Elaine Gallagher, Alka Singh, et al.
Oncology
|
November 29, 2021
Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study
Andrew Briggs, Noman Paracha, Katherine Rosettie, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 28, 2024
Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS
Alicia K Morgans, Jamie Partridge Grossman, Noman Paracha, et al.
Scientific Reports
|
November 13, 2025
Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer
Haiyin Wang, Christopher G Fawsitt, Philip Orishaba, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 6, 2022
Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study
Andrew Briggs, Beth Wehler, Jennifer G Gaultney, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 33) with videos related to
Sort By:
Page
of 4
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
October 20, 2021
Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling
Felicitas Kuehne, Ursula Rochau, Noman Paracha, et al.
Advances in Therapy
|
February 17, 2017
Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial
Alison Griffiths, Noman Paracha, Andrew Davies, et al.
Journal of Medical Economics
|
January 18, 2020
Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France
Sivignon Marine, Roze Stéphane, Plommet Nicolas, et al.
European Urology Focus
|
April 18, 2026
Health-related Quality of Life With ARPIs in mHSPC: Insights From a Network Meta-analysis
Neal D Shore, Noman Paracha, Howard Thom, et al.
Pharmacoeconomics
|
October 18, 2021
Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom
Siu Hing Lo, Ksenija Gorni, C Simone Sutherland, et al.
Pharmacoeconomics
|
August 18, 2025
Developing a Comprehensive Framework for Cost-Effectiveness Evaluation in Metastatic Castration-Sensitive Prostate Cancer: Insights from a Systematic Review
Christopher G Fawsitt, Elaine Gallagher, Alka Singh, et al.
Oncology
|
November 29, 2021
Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study
Andrew Briggs, Noman Paracha, Katherine Rosettie, et al.
Journal of Managed Care & Specialty Pharmacy
|
May 28, 2024
Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS
Alicia K Morgans, Jamie Partridge Grossman, Noman Paracha, et al.
Scientific Reports
|
November 13, 2025
Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer
Haiyin Wang, Christopher G Fawsitt, Philip Orishaba, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 6, 2022
Comparison of Alternative Methods to Assess the Cost-Effectiveness of Tumor-Agnostic Therapies: A Triangulation Approach Using Larotrectinib as a Case Study
Andrew Briggs, Beth Wehler, Jennifer G Gaultney, et al.
Page
of 4